TriangleNCT01259856 · OUTCOME
Number of Participants With Progression of Disease or Death
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- 4 years
What was measured
Survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy To estimate survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) by capturing the rate of progression to a more advanced myeloid malignancy.
Groups in this outcome
PEGASYS
The subject received the PEGASYS at a dose level of 45 micrograms weekly and gradually increased to the maximum dose of 180 micrograms per week. The dose was administered by prefilled syringes and injected subcutaneously. Subjects received therapy for up to 12 months. Aspirin: Subject asked to take 81 to 100mg per day for the 12 months of the study treatment.
Hydroxyurea
Subjects received a 500mg tablet to be taken twice daily for up to 12 months of treatment. Aspirin: Subject asked to take 81 to 100mg per day for the 12 months of the study treatment.
| Group | Source count |
|---|---|
| PEGASYS | 82 |
| Hydroxyurea | 86 |
Reported measurements
Death
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| PEGASYS | 0 | Not reported | Not reported | Not reported | Not reported |
| Hydroxyurea | 1 | Not reported | Not reported | Not reported | Not reported |
Progression to MF
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| PEGASYS | 0 | Not reported | Not reported | Not reported | Not reported |
| Hydroxyurea | 0 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 1
- title
- Death
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- title
- Progression to MF
- denoms
- counts
- group Id
- OG000
- value
- 82
- group Id
- OG001
- value
- 86
- units
- Participants
- description
- Survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy To estimate survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) by capturing the rate of progression to a more advanced myeloid malignancy.
- groups
- description
- The subject received the PEGASYS at a dose level of 45 micrograms weekly and gradually increased to the maximum dose of 180 micrograms per week. The dose was administered by prefilled syringes and injected subcutaneously. Subjects received therapy for up to 12 months. Aspirin: Subject asked to take 81 to 100mg per day for the 12 months of the study treatment.
- id
- OG000
- title
- PEGASYS
- description
- Subjects received a 500mg tablet to be taken twice daily for up to 12 months of treatment. Aspirin: Subject asked to take 81 to 100mg per day for the 12 months of the study treatment.
- id
- OG001
- title
- Hydroxyurea
- param Type
- COUNT_OF_PARTICIPANTS
- reporting Status
- POSTED
- time Frame
- 4 years
- title
- Number of Participants With Progression of Disease or Death
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice